Panbela Therapeutics (PBLA) News Today → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free PBLA Stock Alerts $0.43 +0.03 (+7.78%) (As of 10:12 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 8:58 AM | uk.finance.yahoo.comQ1 2024 Panbela Therapeutics Inc Earnings CallMay 16 at 8:58 AM | msn.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2024 Earnings Call TranscriptMay 16 at 3:57 AM | finance.yahoo.comPanbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 15 at 4:10 PM | globenewswire.comPanbela Provides Business Update and Reports Q1 2024 Financial ResultsMay 6, 2024 | finance.yahoo.comPanbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacMay 6, 2024 | globenewswire.comPanbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacMay 1, 2024 | globenewswire.comPanbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024April 30, 2024 | globenewswire.comAcceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekApril 22, 2024 | globenewswire.comPanbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025April 18, 2024 | marketwatch.comPanbela Applies to List on CBOEApril 18, 2024 | globenewswire.comPanbela Announces Poster Presentation at American Association for Cancer Research:April 17, 2024 | finanznachrichten.dePanbela Therapeutics, Inc.: Panbela Announces Transfer to OTCQB MarketApril 16, 2024 | finance.yahoo.comPanbela Announces Transfer to OTCQB MarketMarch 28, 2024 | benzinga.comRecap: Panbela Therapeutics Q4 EarningsMarch 28, 2024 | seekingalpha.comPanbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | msn.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finanznachrichten.dePanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsMarch 26, 2024 | globenewswire.comPanbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsMarch 26, 2024 | benzinga.comEarnings Preview: Panbela TherapeuticsMarch 22, 2024 | seekingalpha.comPBLA Panbela Therapeutics, Inc.March 12, 2024 | globenewswire.comPanbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024February 23, 2024 | msn.comTop 4 Health Care Stocks That Are Preparing To Pump This MonthFebruary 23, 2024 | benzinga.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)February 15, 2024 | finance.yahoo.comPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsFebruary 15, 2024 | globenewswire.comPanbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsFebruary 1, 2024 | finance.yahoo.comPanbela Announces Closing of Approximately $9.0 Million Public OfferingJanuary 31, 2024 | investing.comPanbela Therapeutics Inc (PBLA)January 30, 2024 | finanznachrichten.dePanbela Therapeutics, Inc.: Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)January 30, 2024 | benzinga.comWhat's Going On With Panbela Therapeutics Stock Today?January 30, 2024 | finance.yahoo.comAcceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)January 29, 2024 | msn.comPanbela Therapeutics, Processa Pharmaceuticals among healthcare moversJanuary 29, 2024 | markets.businessinsider.comPanbela Therapeutics Prices $9 Mln Share OfferingJanuary 29, 2024 | investorplace.comWhy Is Panbela Therapeutics (PBLA) Stock Down 63% Today?January 29, 2024 | marketwatch.comPanbela Therapeutics Shares Slide Premarket After Public OfferingJanuary 29, 2024 | msn.comPanbela Therapeutics drops on $9M public offeringJanuary 29, 2024 | finance.yahoo.comPanbela Announces Pricing of Approximately $9.0 Million Public OfferingJanuary 26, 2024 | msn.comWhat's Going On With Panbela Therapeutics Stock?January 26, 2024 | marketbeat.comTrading was temporarily halted for "PBLA" at 09:01 AM with a stated reason of "LULD pause."January 25, 2024 | finance.yahoo.comPanbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated MomentumJanuary 23, 2024 | marketbeat.comTrading was temporarily halted for "PBLA" at 09:01 AM with a stated reason of "LULD pause."January 22, 2024 | marketwatch.comPanbela Therapeutics Touch 52-Week Low on Planned Public OfferingJanuary 18, 2024 | marketbeat.comTrading was temporarily halted for "PBLA" at 01:01 PM with a stated reason of "LULD pause." Trading set to resume at 01:01 PM. January 18, 2024 | finance.yahoo.comPanbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialJanuary 18, 2024 | marketbeat.comTrading was temporarily halted for "PBLA" at 07:01 PM with a stated reason of "News pending."January 16, 2024 | finance.yahoo.comPanbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024December 21, 2023 | morningstar.comPanbela Therapeutics' stock skyrockets after positive FDA news on child cancer treatmentDecember 21, 2023 | finance.yahoo.comPanbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-MarketDecember 20, 2023 | msn.comPanbela Therapeutics (PBLA) Stock Is Down 25%: What's Going On?December 19, 2023 | msn.comWhat In The World Is Going On With Panbela Therapeutics (PBLA) Stock?December 18, 2023 | realmoney.thestreet.comPanbela Therapeutics at Roth MKM, here's why Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (Ad)Nanoviricides Technology Will Transform The Way Viruses & Their Variants Are Treated Worldwide And This Company Is At The Forefront! See how with its ongoing expansion and development PBLA Media Mentions By Week PBLA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PBLA News Sentiment▼0.000.55▲Average Medical News Sentiment PBLA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PBLA Articles This Week▼22▲PBLA Articles Average Week Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lucy Scientific Discovery News Today Biodexa Pharmaceuticals News Today GRI Bio News Today NeuBase Therapeutics News Today InMed Pharmaceuticals News Today Sunshine Biopharma News Today 180 Life Sciences News Today PainReform News Today Allarity Therapeutics News Today Evelo Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PBLA) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldDoes this make you sick?Allegiance GoldTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
